Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide +/- Capecitabine in Advanced Pancreatic Neuroendocrine Tumors
NCT01824875Phase 2Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Aug 2013
- Primary completion
- May 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Progression-free Survival at 60 months. Started Aug 2013; status: completed.
02
Drugs
capecitabine
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01824875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824875.